SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-285904
Filing Date
2019-11-06
Accepted
2019-11-06 16:11:10
Documents
14
Period of Report
2019-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d820238d8k.htm   iXBRL 8-K 27183
2 EX-99.1 d820238dex991.htm EX-99.1 24842
6 GRAPHIC g820238g1106120428859.jpg GRAPHIC 1899
  Complete submission text file 0001193125-19-285904.txt   182046

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fprx-20191106.xsd EX-101.SCH 3073
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20191106_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20191106_pre.xml EX-101.PRE 10955
8 EXTRACTED XBRL INSTANCE DOCUMENT d820238d8k_htm.xml XML 3258
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 191196403
SIC: 2834 Pharmaceutical Preparations